Abstract: Antibodies binding to human claudin 18.2 (CLDN 18.2) and bispecific antibodies binding to both human CLDN 18.2 and PD-L1, pharmaceutical compositions comprising such, and methods of using such for treating target diseases including cancer.

Abstract: Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin18.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies), and/or by combination therapies where the anti-claudin18.2 antibodies are administered before, after, or concurrently with chemotherapy.

Abstract: Antibodies specifically binding to human program death-ligand 1 (PDL1) with high binding affinity, pharmaceutical compositions comprising such, and methods of using such for treating a target disease such as cancer.

Abstract: Antibodies binding to human claudin 18.2 (CLDN 18.2) and bispecific antibodies binding to both human CLDN 18.2 and PD-L1, pharmaceutical compositions comprising such, and methods of using such for treating target diseases such as cancer.

Abstract: Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin18.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies), and/or by combination therapies where the anti-claudin18.2 antibodies are administered before, after, or concurrently with chemotherapy.

Abstract: Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin18.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies), and/or by combination therapies where the anti-claudin18.2 antibodies are administered before, after, or concurrently with chemotherapy.

Abstract: Methods and compositions are provided for studying and targeting RNA structures. In particular, antibodies and antibody fragments that contain an Fab were produced. Phage display libraries that were engineered to produce RNA-specific antibody and antibody fragments were made. Antibodies, or fragments thereof, that have at least one Fab that specifically binds tRNAiMet, the P4-P6 domain of Tetrahymena Group I intron, the glycine riboswitch from Vibrio Cholerae, or the glycine riboswitch from Fusobacterium Nucleatum were identified. The production of these RNA-specific antibodies and antibody fragments can be used to study the structure of the RNA as well as to treat diseases with known RNA targets. For example, an Fab specific to tRNAiMet was produced that can be used to treat cancer in subjects where tRNAiMet is overexpressed.

Abstract: A switching system includes at least one packet processing circuit interfacing with at least one packet transmission link. The switching system further includes a switch fabric coupled to the at least one packet processing circuit, whereby the switch fabric is operable to switch between channels receiving and transmitting data over the at least one packet transmission link and channels receiving and transmitting data over at least one non-packet transmission link interfaced by the switch fabric.

Abstract: A switching system includes at least one packet processing circuit interfacing with at least one packet transmission link. The switching system further includes a switch fabric coupled to the at least one packet processing circuit, whereby the switch fabric is operable to switch between channels receiving and transmitting data over the at least one packet transmission link and channels receiving and transmitting data over at least one non-packet transmission link interfaced by the switch fabric.

Abstract: A switching system includes at least one packet processing circuit interfacing with at least one packet transmission link. The switching system further includes a switch fabric coupled to the at least one packet processing circuit, whereby the switch fabric is operable to switch between channels receiving and transmitting data over the at least one packet transmission link and channels receiving and transmitting data over at least one non-packet transmission link interfaced by the switch fabric.

Abstract: A switching system includes at least one packet processing circuit interfacing with at least one packet transmission link. The switching system further includes a switch fabric coupled to the at least one packet processing circuit, whereby the switch fabric is operable to switch between channels receiving and transmitting data over the at least one packet transmission link and channels receiving and transmitting data over at least one non-packet transmission link interfaced by the switch fabric.